

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number  
**WO 01/93859 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/22**,  
31/366, 31/404, 47/02

(21) International Application Number: PCT/IB00/00771

(22) International Filing Date: 9 June 2000 (09.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **LEK  
PHARMACEUTICAL AND CHEMICAL COMPANY  
D.D.** [SI/SI]; Verovskova 57, 1526 Ljubljana (SI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PFLAUM, Zlatko**  
[SI/SI]; Češminova 23, 1230 Domžale (SI). **MILIVO-  
JEVIC, Dušan** [SI/SI]; Tbilisijska 88, 1000 Ljubljana  
(SI). **RUČMAN, Boris** [SI/SI]; Spodnje Gameljne 72,  
1211 Ljubljana (SI). **KOGEJ, Stojan** [SI/SI]; Sneberško  
Nabrežje 60, 1260 Ljubljana (SI).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



**WO 01/93859 A1**

(54) Title: STABLE PHARMACEUTICAL PRODUCT AND FORMULATION

(57) Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives thereof are known as HMG-CoA reductase inhibitors and are used for the treatment of hypercholesterolemia and hyperlipidemia. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to *Aspergillus*, *Monascus*, *Nocardia*, *Amycolatopsis*, *Mucor* or *Penicillium* genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilised by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a product or a pharmaceutical package or administration material which contains a HMG-CoA reductase inhibitor or a pharmaceutical formulation in a stable manner.

**BEST AVAILABLE COPY**

- 1 -

## Stable pharmaceutical product and formulation

### Field of the Invention

The present invention relates to a new concept of  
5 stabilizing a HMG-CoA reductase inhibitor which is used in a  
pharmaceutical formulation being particularly suitable for  
the treatment of hypercholesterolemia and hyperlipidemia.  
More precisely, the present invention relates to a  
stabilized product comprising a HMG-CoA reductase inhibitor,  
10 such as atorvastatin, pravastatin, fluvastatin and  
cerivastatin, or pharmaceutically active salts thereof, as  
well as to a pharmaceutical package or administration  
material containing the HMG-CoA reductase inhibitor as an  
active substance. The present invention also relates to a  
15 process for producing such stable pharmaceutical packaging  
or administration materials.

### Background of the Invention

Lovastatin, pravastatin, simvastatin, mevastatin,  
20 atorvastatin, fluvastatin and cerivastatin, derivatives and  
analogues thereof are known as HMG-CoA reductase inhibitors  
and are used as antihypercholesterolemic agents. The  
majority of them are produced by fermentation using  
microorganisms of different species identified as species  
25 belonging to *Aspergillus*, *Monascus*, *Nocardia*, *Amycolatopsis*,  
*Mucor* or *Penicillium* genus. Some are obtained by treating  
the fermentation products using the methods of chemical  
synthesis like simvastatin or they are the products of total  
chemical synthesis like fluvastatin, atorvastatin and  
30 cerivastatin.

The purity of the HMG-CoA reductase inhibitor as the  
active substance is an important factor for manufacturing a  
safe and effective pharmaceutical formulation. Maximum  
35 possible purity of the product is of particular importance  
if the pharmaceutical product must be taken on a longer term

CONFIRMATION COPY

- 2 -

basis in the treatment or prevention of high cholesterol levels in blood. Accumulation of impurities from drugs of a lower level of purity may cause a variety of side effects during treatment. Besides impurities, that cannot be  
5 completely eliminated in the process of preparation of the active substance, degradation products occurring by subjecting the final pharmaceutical formulation to various environmental factors such as temperature, moisture, low pH and light, may also impose a problem. HMG-CoA reductase  
10 inhibitors occurring in the form of salts in the final pharmaceutical formulation, such as atorvastatin, pravastatin, fluvastatin and cerivastatin, are particularly sensitive to an acidic environment in which hydroxy acids are degraded into a lactone.

15

Apart from the fact that the aforementioned active substance may be destabilised by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers,  
20 binders, lubricants, glidants and disintegrating agents. Therefore, the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions.

25

The stability of the active substance in an acidic environment is one of the major problems in the case of statins in the form of salts. For example, the sodium salt of pravastatin provides a pH between 7 and 8.5, normally  
30 around 7.5, when brought into a water solution at a concentration of 5 wt.-%. At this pH, not only the solid form but also dissolved pravastatin Na slowly converts into pravastatin lactone, which is to be considered as impurity and degradation product. As a possible solution of this  
35 problem, EP 0 336 298 proposes a stable pharmaceutical formulation for pravastatin. The essence of the formulation

- 3 -

is to maintain an alkaline environment so that the aqueous dispersion of the pharmaceutical formulation reaches a pH above 9, preferably about 10. In addition to the active substance pravastatin, the composition of the invention includes a basifying agent, such as magnesium oxide which imparts a pH to an aqueous dispersion of the aforementioned formulation above 9. In view of the stability of the active substance such a formulation is effective. However, the local alkaline environment occurring at the site of dissolution of the pharmaceutical formulation may have a negative impact on the gastric mucosa with its normally acidic environment. This negative impact may be particularly evident for patients with a damaged gastric mucous membrane where the mucosa per se is not able to create a sufficient acidic environment inside the stomach for normal digestive functioning. It is particularly important in chronic therapies as in the case of prophylaxis or treatment with HMG-CoA reductase inhibitors.

Other approaches for providing a stable pharmaceutical formulation are described in the present Applicant's earlier PCT application No. PCT/IB99/01749, as well as in the present Applicant's PCT application of even date.

#### Summary of the Invention

It is an object of the present invention to provide a pharmaceutical formulation containing as an active substance a HMG-CoA reductase inhibitor which exerts an excellent stability while avoiding the afore mentioned disadvantages. It is a particular object to provide a means by which the HMG-CoA reductase inhibitor is precautionary protected from being degraded.

It is a further object to provide a process for a pharmaceutical packaging or administration material, whereby the pharmaceutical formulation containing the HMG-CoA

- 4 -

reductase inhibitor as the active substance can be effectively stabilized.

5 These and further objects are accomplished by the present invention.

According to one aspect of the present invention, there is provided a product comprising a HMG-CoA reductase inhibitor and a substance capable of binding and/or  
10 neutralizing carbon dioxide.

According to another aspect of the present invention, the aforementioned product is represented by a pharmaceutical package or administration material, wherein  
15 the HMG-CoA reductase inhibitor is contained in at least one pharmaceutical formulation unit, and wherein, separated from the HMG-CoA reductase inhibitor-containing, at least one formulation unit, said substance capable of binding and/or neutralizing carbon dioxide.

20

According to the present invention, there is also provided a process of producing a pharmaceutical packaging or an administration material which contain one or more formulations of a HMG-CoA reductase inhibitor, which process  
25 comprises the step of incorporating a substance capable of binding and/or neutralizing carbon dioxide into the pharmaceutical packaging or administration material.

In the inventor's investigations, it was found that  
30 carbon dioxide from the air can bind, normally partly reversible and partly irreversible, to the HMG-CoA reductase inhibitor as the active substance. This binding of carbon dioxide can cause a drop of pH within the HMG-CoA reductase inhibitor substance in bulk or within the HMG-CoA reductase  
35 inhibitor-containing pharmaceutical formulation and, thus, represents a major reason for instability problems in case

- 5 -

of a pharmaceutical formulation containing an active substance and in case of a bulk active substance. Even if a non-stabilized HMG-CoA reductase inhibitor-containing pharmaceutical formulation is packed under nitrogen  
5 atmosphere but was before exposed to normal atmosphere, the pH which would be generated when obtaining an aqueous solution thereof is slowly going down and eventually leads to an increase in impurities and degradation products. By means of the particular combination of a HMG-CoA reductase  
10 inhibitor and a substance capable of binding and/or neutralizing carbon dioxide in accordance with the present invention, a strong protective effect is achieved.

With addition of carbon dioxide binding and/or  
15 neutralizing substance, the pH decrease is effectively lowered or ceased. The carbon dioxide binding and/or neutralizing substance can remove the carbon oxide which may already be present in the HMG-CoA reductase inhibitor as such (in bulk) before being formulated into the  
20 pharmaceutical formulation, but can also remove the carbon dioxide which may be present in, and which may pass into the packaging or administration material such as bags or bottles.

25 Moreover, since already the HMG-CoA reductase inhibitor as such (in bulk) may be efficiently protected against deleterious environmental factors when combined with the carbon dioxide binding and/or neutralizing substance within the product of the present invention, the HMG-CoA reductase  
30 inhibitor can be handled more conveniently and stably stored as such, if desired, before being added to the pharmaceutical formulation.

Furthermore, by using the carbon dioxide binding and/or  
35 neutralizing substance according to the present invention, both the product before being added to the pharmaceutical

- 6 -

formulation as well as the final pharmaceutical package or administration material are highly resistant to the negative effects of both carbon dioxide from the air, and a much better protection against low pH conditions is achieved.

5

#### Brief description of the drawings

Figures 1a and 1b show HPLC chromatograms of unstabilized pravastatin Na (Fig. 1a) and of unstabilized pravastatin Na after the exposure to carbon dioxide atmosphere (Fig. 1b), showing the formation of different degradation products (impurities) of unstabilized and unprotected pravastatin.

Figure 2 is a graph which shows the change or the maintenance of pH over time when a sample of unstabilized pravastatin is either protected against carbon dioxide according to the invention or not protected when exposed to air.

20

Figure 3 is a graph which shows the change or the maintenance of pH over time when a sample of stabilized pravastatin is either protected against carbon dioxide according to the invention or not protected when exposed to carbon dioxide atmosphere.

25

#### Detailed description of the preferred embodiments

In the present invention, we have surprisingly found that a sufficient stability of the active substance, which is a HMG-CoA reductase inhibitor preferably in the form of salt, can be also obtained by using an approach which does not require basifying the active substance-containing pharmaceutical formulation to provide a pH of at least 9 and thus does not create a marked alkaline environment in an aqueous solution or dispersion of the pharmaceutical

35

- 7 -

formulation. In order to achieve this efficiently, it is significant that the HMG-CoA reductase inhibitor is combined with the carbon dioxide binding and/or neutralizing substance.

5

In the first aspect of the present invention, the particular combination is provided within a product as desired. The product is appropriately designed such that the carbon dioxide binding and/or neutralizing substance can exert its effects of precautionary protecting the HMG-CoA reductase inhibitor. In case that the type of the carbon dioxide binding and/or neutralizing substance, which possible types will be described below, is pharmaceutically acceptable it may be incorporated directly into either the HMG-CoA reductase inhibitor as such (in bulk) or the pharmaceutical formulation containing the HMG-CoA reductase inhibitor as the active substance, such as in case of using appropriate buffering or basifying substances. In this embodiment, it is advantageous when the buffering or basifying substance which binds or neutralizes carbon dioxide is physically mixed with the HMG-CoA reductase inhibitor as such (in bulk), because this measure provides an efficient protection in the early stage of processing the active substance and of fabricating the pharmaceutical formulation. Alternatively, the carbon dioxide binding and/or neutralizing substance may be provided in an element or a compartment of a package or pharmaceutical administration material, which element or compartment is separated from the element or compartment containing either the HMG-CoA reductase inhibitor in bulk or the pharmaceutical formulation. The latter embodiment is suitable for carbon dioxide binding and/or neutralizing substances which are not pharmaceutically acceptable. This is advantageous, because pharmaceutically unacceptable substances are known which bind, neutralize and/or react with carbon dioxide in a very strong and fast manner, such



- 8 -

as molecular sieves, superoxides or alkali metal hydroxides. Carbon dioxide can thus be removed from the atmosphere which is present in the package or pharmaceutical administration material in a very efficient way. In a further embodiment, 5 the aforementioned direct and especially the aforementioned separate combination with the carbon dioxide binding and/or neutralizing substance may also be provided in an intermediate product during the manufacture of, or after the isolation and purification of the HMG-CoA reductase 10 inhibitor. With this concept, it is possible to achieve sufficient protection from the negative impact of carbon dioxide during the manufacturing, during the handling and during the shipping of the HMG-CoA reductase inhibitor compound as such. Accordingly, in a further embodiment the 15 HMG-CoA reductase inhibitor and the carbon dioxide binding and/or neutralizing substance may be respectively contained in separate elements of a storing or shipping package.

If not already protected or if further protection 20 against carbon dioxide is desired, according to the second aspect of the present invention both the HMG-CoA reductase inhibitor, which is incorporated into a pharmaceutical formulation together with appropriate further additives to provide at least one pharmaceutical formulation unit, and 25 the aforementioned carbon dioxide binding and/or neutralizing substance are provided in separate elements or compartments of a pharmaceutical package or administration material. The kind and shape of the pharmaceutical formulation unit and the elements or compartments containing 30 it, of the elements or compartments containing the carbon dioxide binding and/or neutralizing substance, and of the pharmaceutical package or administration material is not critical and may be designed as desired. The pharmaceutical formulation unit usually is a solid pharmaceutical dosage 35 form such as compressed tablet or capsules. The solid pharmaceutical dosage form such as tablets or capsules may

- 9 -

be placed into appropriate dosage form containers to form the pharmaceutical package or administration material, such as plastic bags, blister packages metal bags or glass bottles. The carbon dioxide binding and/or neutralizing  
5 substance may be placed in an appropriate separate element or compartment within the pharmaceutical package or administration material, such as a porous or perforated body, a gas permeable bag or jar, a permeable or semipermeable membrane, or the like.

10


The pharmaceutical package or administration material which contains one or more formulations of a HMG-CoA reductase inhibitor can be suitably produced according to the present invention by a process comprising the step of  
15 incorporating the substance capable of binding and/or neutralizing carbon dioxide into the pharmaceutical packaging or administration material. Furthermore, in producing the pharmaceutical package or administration material according to the present invention, the separate  
20 element or compartment containing the carbon dioxide binding and/or neutralizing substance may be incorporated into the pharmaceutical package or administration material under nitrogen atmosphere in order to further reduce carbon oxide content.

25

In the product according to the first aspect and in the pharmaceutical package or administration material according to the second aspect of the present invention, while the element or compartment containing the carbon dioxide binding  
30 and/or neutralizing substance is permeable or semipermeable to the environment inside the product or the pharmaceutical package or administration material, the product or the pharmaceutical package or administration material respectively are preferably sealed or airtightly closed to  
35 prevent further negative impact from the carbon dioxide of the outside air.

- 10 -

The HMG-CoA reductase inhibitor and the pharmaceutical



5 further detail. This pharmaceutically active substance may  
be selected from the group consisting of pravastatin,  
atorvastatin, fluvastatin, cerivastatin and a  
pharmaceutically acceptable salt thereof. Preferably, the  
active substance is in the form of a solid salt. The  
10 resistance against carbon dioxide is particularly effective  
when the HMG-CoA reductase inhibitor is the sodium salt of  
pravastatin (pravastatin Na) or the calcium salt of  
atorvastatin (atorvastatin Ca). Nonetheless, the stabilizing  
effect is also achieved when using other HMG-CoA reductase  
15 inhibitors.

In preferred embodiments, the HMG-CoA reductase  
inhibitor and/or the pharmaceutical formulation is/are  
further stabilized against moisture and pH sensitivity. We

- 11 -

medium containing said active substance or the formulation would be measured.

The preferred additional stabilization is suitably effected by the addition of buffering or basifying substances to the HMG-CoA reductase inhibitor in bulk, or by the addition of buffering or basifying substances to the pharmaceutical formulation, as described in aforementioned application PCT/IB/01749 and in the present Applicants' PCT application of even date which is also incorporated herein by way of reference.

When added to the HMG-CoA reductase inhibitor in bulk, the amount of buffering agent or basifying substance may be relatively small. Accordingly, the active substance may contain a buffering agent or a basifying substance at an amount ratio of the buffering substance or the basifying substance of 30 wt.-% or below, preferably 10 wt.-% or below, more preferably 5 wt.-% or below and in particular 1 wt.-% or below, relative to the amount of HMG-CoA reductase inhibitor. The preferred lower limit mainly depends on the environmental conditions and the kind and amounts of other components to be used for the pharmaceutical formulation, but an amount of at least 0.05 or 0.1 wt.-% of the buffering substance or the basifying substance, relative to the amount of HMG-CoA reductase inhibitor, may be used. For example, an amount 0.3% of sodium carbonate in pravastatin results in a pH of pravastatin between 9 and 10. Thus, it is possible to mix HMG-CoA reductase inhibitor like pravastatin with other ingredients of the pharmaceutical formulation without fear that a degradation can be caused by the contact of pravastatin with acidic ingredients as a microenvironment of pravastatin is still basic due to the addition of small amounts of a buffering agent.

- 12 -

When added to the pharmaceutical formulation as desired, optionally in addition to the admixture or the homogeneous composition with the HMG-CoA reductase inhibitor in bulk, the buffering agent or basifying substance may be  
5 used in amounts of 20% or less, preferably 10% per weight or less based on the total weight of the pharmaceutical formulation.

If used, any buffering or basifying substance capable  
10 of adjusting the pH of the total formulation in the desired range is suitable. The buffering substance or agent is suitable selected from the group consisting of salts of inorganic acids, salts of organic bases or salts of organic acids. Examples of salts of inorganic acids include sodium  
15 or potassium citrate, sodium or potassium phosphate or hydrogen phosphate, dibasic sodium phosphate, sodium, potassium, magnesium or calcium carbonate or hydrogen carbonate, sulphate, or mixtures of such buffering agents, or the like; carbonate buffer or phosphate buffer, such as  
20 sodium carbonate or sodium phosphate, being preferred. Examples for salts of organic bases include aminoguanidine carbonate or hydrogen carbonate, guanidine carbonate or hydrogen carbonate, succinimide carbonate or hydrogen carbonate, 1-adamantil amine carbonate or hydrogen  
25 carbonate, N,N'-bis(2-hydroxyethyl) ethylenediamine carbonate or hydrogen carbonate, tris (hydroxymethyl) aminomethane carbonate or hydrogen carbonate, D(-)-N-Methylglucamine carbonate or hydrogen carbonate, or the like. Examples for salts of organic acids include potassium or sodium salts of  
30 acetic acid, citric acid, lactic acid, ascorbic acid, maleic acid, phenylacetic acid, benzoic acid, lauryl sulphuric acid, or the like. The basifying substance or agent is suitable selected from the group consisting of metal oxides, inorganic bases, organic bases and organic acids with basic  
35 character. Examples of metal oxides include magnesium oxide and aluminum oxide. Examples of inorganic bases include

- 13 -

alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, alkali earth metal hydroxide such as calcium hydroxide or magnesium hydroxide. Examples of organic bases include succinimide, 1-adamantyl amine, N,N'-bis(2-  
5 hydroxyethyl) ethylenediamine, tris (hydroxymethyl) aminomethan, D(-)-N-methylglucamine, or the like. Examples of organic acids with basic character include 3-(N-morpholino)propanesulfonic acid, 4-[cyclohexyl amino]-1-butansulfonic acid, 4-[cyclohexyl amino]-1-etansulfonic acid,  
10 the salts of these organic acids with alkaline or alkaline earth metals, and further include arginine, ornithine, lysine, or the like.

The carbon dioxide binding and/or neutralizing  
15 substance utilized in the first and second aspect of the present invention will now be described in further detail. The concept of binding and/or neutralizing includes any possibility of removing carbon dioxide or preventing it from interacting with the HMG-CoA reductase inhibitor.  
20 Accordingly, this substance may be selected from the group of compounds which are effective for adsorbing, absorbing and/or neutralizing carbon dioxide and/or reacting therewith, or any combination of these measures. The affinity of the substance used towards carbon dioxide by  
25 means of binding, neutralizing and/or reacting is preferably much higher than the respective affinity of HMG-CoA reductase inhibitor like pravastatin Na towards carbon dioxide in order to provide a significant protective effect.

30 Compounds for adsorbing includes hydrophobic adsorbers such as activated carbon or charcoal, activated coke or carbon molecular sieves, and preferably hydrophilic adsorbers such as zeolites and other hydrophilic molecular sieves, silica gel, activated aluminum oxide and Fuller's  
35 earth. The adsorbing compounds have appropriate pores for effectively adsorbing carbon dioxide, as described, for

- 14 -

example, in "Ullmann's Encyclopedia of Industrial Chemistry", 5<sup>th</sup> edition (1988), Vol. B-3, Chapter 9.

Preferred adsorbing compounds are zeolites, and particularly the zeolite types 5A, 4A, 10X and 13X.

5

Compounds for absorbing includes those physically and those chemically absorbing carbon dioxide, the latter also embracing the concept of chemically reacting with carbon dioxide, possibly in addition. Preferred examples, which are particularly effective for the purpose of the present invention, are alkali metal hydroxides or alkali metal superoxides. Particularly preferred are potassium superoxide and the alkali metal hydroxides KOH, NaOH and LiOH.

15 Further examples for the binding of carbon dioxide are membranes or hollow fibers made of polymers and having an asymmetric pore structure, possibly additionally provided with an active layer of e.g. siloxane. Possible polymers are cellulose acetate or triacetate, silicone, polysulfone and polycarbonate, or composites thereof, as described in "Ullmann's Encyclopedia of Industrial Chemistry", 5<sup>th</sup> edition, Vol. A-17, 1991, pp. 73-124 and Vol. A-13, 1989, pp. 297-442.

25 Compounds for neutralizing, and possibly also absorbing and/or reacting with, carbon dioxide includes appropriate buffering substances and appropriate basifying substances, such as the buffering and basifying substances mentioned above as being also effective for adjusting the pH. For neutralizing carbon dioxide; alkali metal hydroxides, alkali metal carbonates and alkali metal bicarbonates are particularly effective. Since buffering substances per se do not have, in comparison with other carbon dioxide binding substances mentioned above, such a strong affinity towards binding and/or neutralizing carbon dioxide from the atmosphere within the package or pharmaceutical

- 15 -

administration material, it is preferred that such buffering substances are physically mixed directly with the HMG-CoA reductase inhibitor, especially with this active substance itself (in bulk) as already described above. In this case, a  
5 stabilization against the negative influences of pH and moisture and a protection against carbon dioxide are achieved at the same time. An efficient overall protection against various negative influencing factors can be obtained when a buffering or basifying substance is mixed in a  
10 physical manner with the HMG-CoA reductase inhibitor in bulk or with the pharmaceutical formulation, and in addition another substance which removes carbon dioxide from the atmosphere present in the pharmaceutical package or administration material is used in a separate element  
15 thereof as described above.

Thus, the above mentioned carbon dioxide binding and/or neutralizing substances may be used alone or in combination. Furthermore, the binding of moisture or the reaction or co-  
20 reaction with water vapor may occur at the same time. The forms of the substances are not critical and may dependent on the kind of material used and the design of the packaging or pharmaceutical administration material as desired. For example, the substances may be in the form of powders,  
25 granules, spheres, pellets, tablets, rods, or other moldings or pressed forms. The substances may be incorporated into the packaging or pharmaceutical administration material for example by means of bags or similar elements, but they may be also placed into perforated or permeable bodies which are  
30 connected to parts or elements of the packaging or pharmaceutical administration material such as the screw cap of bottles. If possible in view of the kind of substance, the substance itself may also form at least a part of the packaging material, e.g. when using carbon dioxide binding  
35 polymer membranes.



- 16 -

By following the concepts of the present invention, the HMG-CoA reductase inhibitor as well as the pharmaceutical formulation containing it as the active substance are stable by being resistant against the negative effect of carbon dioxide and do not tend to be decomposed and, thus, essentially retain their activity.

The pharmaceutical formulation used in the invention may include, in addition to the HMG-CoA reductase inhibitor, one or more fillers, such as microcrystalline cellulose, lactose, sugars, starches, modified starch, mannitol, sorbitol and other polyols, dextrin, dextran and maltodextrin, calcium carbonate, calcium phosphate and/or hydrogen phosphate, sulphate, one or more binders, such as lactose, starches, modified starch, dextrin, dextran and maltodextrin, microcrystalline cellulose, sugars, polyethylene glycols, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethylcellulose, hydroxyethyl cellulose, methylcellulose, carboxymethyl cellulose, gelatin, acacia gum, tragacanth, polyvinylpyrrolidone, magnesium aluminium silicate, one or more disintegrating agents such as croscarmellose sodium, cross-linked polyvinylpyrrolidone, cross-linked carboxymethyl starch, starches and microcrystalline cellulose, magnesium aluminium silicate, polyacrylin potassium, one or more different glidants such as magnesium stearate, calcium stearate, zinc stearate, calcium behenate, sodium stearyl fumarate, talc, magnesium trisilicate, stearic acid, palmitic acid, carnauba wax, silicon dioxide, one or more buffering agents such as sodium or potassium citrate, sodium phosphate, dibasic sodium phosphate, calcium carbonate, hydrogen phosphate, phosphate, sulphate, sodium or magnesium carbonate, sodium ascorbate, benzoate, sodium or potassium hydrogen carbonate, lauryl sulphate, or any mixtures of these.

35

- 17 -

If required any, the formulation may also include surfactants and other conventional components for solid, pharmaceutical formulations such as colouring agents, lakes, aromas and adsorbents. As surfactants the following may be  
5 used: ionic surfactants, such as sodium lauryl sulphate or non-ionic surfactants such as different poloxamers (polyoxyethylene and polyoxypropylene copolymers), natural or synthesized lecithins, esters of sorbitan and fatty acids (such as Span®, manufactured by Atlas Chemie), esters of  
10 polyoxyethylenesorbitan and fatty acids (such as Tween®, manufactured by Atlas Chemie), polyoxyethylated hydrogenated castor oil (such as Cremophor®, manufactured by BASF), polyoxyethylene stearates (such as Brij®, manufactured by Atlas Chemie), dimethylpolysiloxane or any combination of  
15 the above mentioned surfactants.

If the solid pharmaceutical formulation is in the form of coated tablets, the coating may be prepared from at least one film-former such as hydroxypropyl methylcellulose,  
20 hydroxypropyl cellulose, at least from one plasticizer such as polyethylene glycols, dibutyl sebacate, triethyl citrate, and other pharmaceutical auxiliary substances conventional for film coatings, such as pigments, fillers and others.

25 The solid pharmaceutical formulations according to the present invention may be prepared as described below:

- The mixture of the active substance, filler, binder, buffering agent, disintegrating agent and if required a  
30 surfactant and other conventional ingredients for solid pharmaceutical formulations is homogenised employing suitable mixers. Glidants and/or lubricants are added and the mixture is re-homogenised. The resulting mixture is compressed into tablets or filled into capsules. If needed,  
35 tablets can be film-coated.

- 18 -

• The mixture of the active substance, filler, binder, buffering agent, disintegrating agent and if required a surfactant and other conventional ingredients for solid pharmaceutical formulations is homogenised employing

5 suitable mixers, granulated with a suitable solvent such as water, ethanol, methanol, isopropyl alcohol, n-butyl alcohol, acetone, diethyl ether, ethyl acetate, isopropyl acetate, methyl acetate, dichloromethane and methanol, and mixtures of these solvents such as ethanol and acetone,

10 methanol and acetone, dichloromethane and methanol, and the mixtures thereof. The resulting granulation is dried in suitable dryers such as standard plate dryers, fluid bed dryers, vacuum and microwave dryers. To the dried granulation, glidants and/or lubricants and if required

15 other conventional ingredients for solid pharmaceutical formulations are added. The resulting mixture is rehomogenised and compressed into tablets or filled into capsules. Optionally, tablets are film-coated.

20 The present invention is illustrated but by no means limited by the following examples.

#### EXAMPLES

25 The following experiments were done to show the influence of carbon dioxide from the air on the formation of degradation products (impurities) and on the change of pH of pravastatin Na as a representative HMG-CoA reductase inhibitor and to show the improved stability of pravastatin

30 Na in the presence of substances that can bind and/or neutralize carbon dioxide. Pravastatin Na stabilised by the admixture or composition with buffering or basifying substances as described in the Applicants' earlier application PCT/IB99/01749 and the Applicants' co-pending

35 application of even date is very stable and does not show significant change of pH in case of exposure to carbon

- 19 -

dioxide from the air. Therefore the samples, in case of experiments where the correspondingly stabilised pravastatin was used, were exposed to the atmosphere of pure carbon dioxide, so the changes in pH become evident in a relatively short period of time such as a day or two.

#### 1. Degradation of HMG-CoA reductase inhibitor

10

In Fig. 1a, a HPLC chromatogram of a freshly prepared sample of pravastatin Na is shown. The same pravastatin Na was exposed to carbon dioxide atmosphere for one hour, and then a further HPLC chromatogram was prepared (Fig. 1b).

15 From these HPLC chromatograms it is evident that in case of exposure of pravastatin Na to carbon dioxide two different peaks in front of and three peaks after the peak of pravastatin Na appear. These peaks correspond to degradation products of the HMG-CoA reductase inhibitor.

20

#### 2. Carbon dioxide protection with unstabilized HMG-CoA reductase inhibitor

25 Crystals of pravastatin Na were prepared as follows: The sodium salt of pravastatin (1 g) was dissolved in methanol (10 ml) and while stirring ethyl acetate was added. The resulting clear yellow solution was cooled to 8°C and allowed to stand overnight. Formed radiating clusters of thin, long needle-like crystals were filtered, washed with ethyl acetate (20 ml) and dried. Yield: 0.87 g of pale yellow crystals, melting point 172 - 174°C. Crystals have pH 8.3.

35 Pravastatin Na crystals were exposed to air atmosphere in:

- 20 -

- 1a) opened glass bottle protected only against light  
1b) closed polyethylene bag  
1c) closed polyethylene bag with addition of  $\text{KO}_2$  in  
5 separate jar

3. Carbon dioxide protection with stabilized HMG-CoA  
reductase inhibitor

10

After one day when the pH drop to 7.6 the pravastatin Na crystals were re-crystallised with addition of buffers. First 5 g of pravastatin Na was dissolved in 30 ml of MeOH and then

15

- A 0,2% (w/w)  $\text{Na}_2\text{CO}_3$ ,  
B 0,25% (w/w)  $\text{Na}_2\text{HPO}_4$

- 20 was added. The crystals were formed by addition of 400 ml of ethyl acetate containing 2% of water.

Pravastatin Na crystals stabilized by the addition of  
25 buffering substance were exposed to pure carbon dioxide in:

- 2a) opened glass bottle protected only against light in  
carbon dioxide atmosphere  
2b) closed polyethylene bag  
30 2c) closed polyethylene bag with addition of KOH in  
separate jar  
2d) closed polyethylene bag with addition of  $\text{KO}_2$  in  
separate jar

35

- 21 -

#### 4. Results and Observations with Carbon Dioxide Protection

The pH was measured in case of stabilised pravastatin Na in 1% aqueous solution (lower amount of material necessary) and in case of unstabilized pravastatin Na in 5% aqueous solution.

The results for unstabilized pravastatin Na exposed to air is shown in the following Table 1 and illustrated graphically in Fig. 2.

Table 1

time (hours)	1a	1b	1c
0	8.3	8.3	8.3
24	7.6	7.9	8.2

The results for stabilised pravastatin Na exposed to carbon dioxide atmosphere is shown in the following Table 2 and illustrated graphically in Fig. 3.

Table 2

time (h)	2a *	pH A				pH B			
		A2a	A2b	A2c	A2d	B2a	B2b	B2c	B2d
0	7.60	9.60	9.60	9.60	9.60	8.00	8.00	8.00	8.00
1	7.30	9.30	9.60	9.60	9.60	7.70	7.90	8.00	8.00
5	7.14	7.15	8.50	9.10	9.40	7.20	7.70	7.90	7.80
70	7.14	7.15	7.10	9.00	9.30	6.60	7.05	7.20	7.60

\* unstabilized pravastatin Na

- 22 -

It is evident that in case of unstabilized pravastatin Na, even if it is packed under nitrogen atmosphere but was before that exposed to normal atmosphere, pH is slowly going  
5 down. With addition of carbon dioxide binding and/or neutralizing substance the pH decreases only slightly, see sample 1c. This is the result of binding of the carbon dioxide brought with pravastatin Na into the packing, and that carbon dioxide can not be removed only with the  
10 replacement of air atmosphere with nitrogen atmosphere. The carbon dioxide binding and/or neutralizing substances removes also the carbon dioxide which can pass in to the packaging material such as polyethylene bags, metal bags, screw cap bottles.

15

Pravastatin sodium, which is protected from carbon dioxide by the direct incorporation of a buffering substance into the HMG-CoA reductase inhibitor in bulk, is very stabile in normal atmosphere (no change of pH in one week,  
20 not shown). In case of its exposure to carbon dioxide atmosphere the pH change of samples with KOH and KO<sub>2</sub> was significantly reduced in comparison with the non-protected samples, as shown by the Tables above and Figs. 2 and 3.

25 Instead of the HMG-CoA reductase inhibitor itself as used in the above experiments, pharmaceutical formulations containing the same can be used for being protected against carbon dioxide. Using typical amounts of the HMG-CoA reductase inhibitor, the pharmaceutical formulation can be  
30 obtained as described in the earlier PCT application No. PCT/IB99/01749.

- 23 -

**Claims**

1. A product comprising:
  - 5 a) a HMG-CoA reductase inhibitor and
  - b) a substance capable of binding and/or neutralizing carbon dioxide.
2. The product according to claim 1, wherein the  
10 components a) and b) are contained in separate elements of a package or a pharmaceutical administration material.
3. The product according to claim 1 or 2, wherein the HMG-CoA reductase inhibitor of a) is contained in a  
15 pharmaceutical formulation.
4. The product according to any one of claims 1 to 3, wherein the HMG-CoA reductase inhibitor of a) is stabilized by further incorporating a buffering substance or a  
20 basifying substance into the HMG-CoA reductase inhibitor in bulk.
5. The product according to claim 4, wherein the stabilized HMG-CoA reductase inhibitor of a) is capable of  
25 providing a pH in the range from 7 to 12.
6. The product according to claim 4, wherein the stabilized HMG-CoA reductase inhibitor of a) is capable of providing a pH in the range from 8 to 11.  
30
7. The product according to claim 3, wherein the HMG-CoA reductase inhibitor of a) is stabilized by further incorporating a buffering substance or a basifying substance into the HMG-CoA reductase inhibitor-containing  
35 pharmaceutical formulation.



- 24 -


8. The product according to claim 7, wherein the pharmaceutical formulation is capable of providing a pH in the range from 6 to 9.
- 5 9. The product according to claim 7, wherein the pharmaceutical formulation is capable of providing a pH in the range from 7 to 8.5.
- 10 10. The product according any one of the preceding claims, wherein the substance of b) is selected from the group of compounds which are effective for adsorbing, absorbing and/or neutralizing carbon dioxide and/or reacting with carbon dioxide.
- 15 11. The product according to any one of the preceding claims, wherein substance b) is selected from the group consisting of alkali metal hydroxides, alkali metal carbonates, alkali metal hydrogen carbonates and alkali metal superoxides.
- 20 12. The product according to claim 11, wherein substance b) is potassium superoxide.
- 25 13. The product according to claim 11, wherein substance b) is KOH, NaOH or LiOH.
- 30 14. The product according to any one of the preceding claims, wherein the substance of b) is selected from the group consisting of activated carbon, zeolites, silica gel, activated aluminum oxide and Fuller's earth.
15. The product according to claim 14, wherein the substance of b) is a zeolite which binds carbon dioxide.


- 25 -


16. The product according to any one of the preceding claims, wherein the HMG-CoA reductase inhibitor of a) is in the form of a salt.
- 5 17. The product according to any one of the preceding claims, wherein the HMG-CoA reductase inhibitor of a) is selected from the group consisting of pravastatin, atorvastatin, fluvastatin, cerivastatin and pharmaceutically acceptable salts thereof.
- 10 18. A product combination between the sodium salt of pravastatin (pravastatin Na) and a substance capable of binding and/or neutralizing carbon dioxide.
- 15 19. The product combination according to claim 18, wherein the sodium salt of pravastatin and the substance capable of binding and/or neutralizing carbon dioxide are contained in separate elements of a package or a pharmaceutical administration material.
- 20 20. A pharmaceutical package or administration material comprising at least one pharmaceutical formulation unit of a HMG-CoA reductase inhibitor and, separated from said at least one formulation unit, a substance capable of binding and/or neutralizing carbon dioxide.
- 25 21. The pharmaceutical package or administration material according to claim 20, wherein said HMG-CoA reductase inhibitor is the sodium salt of pravastatin.
- 30 22. A process of producing a pharmaceutical packaging or an administration material which contains one or more formulations of a HMG-CoA reductase inhibitor, which process comprises the step of incorporating a substance capable of binding and/or neutralizing carbon dioxide into the pharmaceutical packaging or administration material.
- 35

- 26 -


23. The process according to claim 21, wherein said substance capable of binding and/or neutralizing carbon dioxide is incorporated into the pharmaceutical packaging or  
5 administration material in an element which is separated from the one or more formulations of a HMG-CoA reductase inhibitor.



**FIG. 1 B**

**FIG. 2**

**Fig. 3**



## INTERNATIONAL SEARCH REPORT

ational Application No

PCT/IB 00/00771

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/22 A61K31/366 A61K31/404 A61K47/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 336 298 A (SQUIBB) 11 October 1989 (1989-10-11) claims	1-23
A	EP 0 547 000 A (SANDOZ) 16 June 1993 (1993-06-16) claims	1-23
A	WO 00 21525 A (NOVARTIS) 20 April 2000 (2000-04-20) examples claims	1-23
A	US 5 225 202 A (G.R.HODGES ET AL. ) 6 July 1993 (1993-07-06) claims	1-23

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the International search

30 January 2001

Date of mailing of the International search report

08/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U



Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 336298	A	11-10-1989	US 5030447 A	09-07-1991
			AT 79030 T	15-08-1992
			AU 3027689 A	05-10-1989
			CA 1323836 A	02-11-1993
			CN 1036508 A,B	25-10-1989
			CY 1675 A	10-10-1993
			DE 68902344 D	10-09-1992
			DE 68902344 T	07-01-1993
			DK 155689 A	01-10-1989
			HK 40093 A	30-04-1993
			IE 62956 B	08-03-1995
			JP 2006406 A	10-01-1990
			JP 2935220 B	16-08-1999
			NZ 228076 A	26-04-1991
			SG 107292 G	24-12-1992
			US 5180589 A	19-01-1993
			ZA 8901424 A	25-10-1989
EP 547000	A	16-06-1993	AT 401872 B	27-12-1996
			AT 190595 A	15-05-1996
			AT 401870 B	27-12-1996
			AT 244992 A	15-05-1996
			AU 661075 B	13-07-1995
			AU 3006992 A	17-06-1993
			CA 2085037 A	13-06-1993
			CH 684309 A	31-08-1994
			CZ 9203633 A	15-09-1993
			CY 1994 A	05-09-1997
			DE 4240430 A	17-06-1993
			DK 547000 T	26-06-2000
			ES 2142819 T	01-05-2000
			FI 925615 A	13-06-1993
			FR 2684876 A	18-06-1993
			GB 2262229 A,B	16-06-1993
			GR 3032929 T	31-07-2000
			HK 25597 A	06-03-1997
			HU 63328 A,B	30-08-1993
			IL 104041 A	27-12-1998
			IT 1256698 B	12-12-1995
			JP 2774037 B	09-07-1998
			JP 5246844 A	24-09-1993
			KR 253824 B	01-05-2000
			LU 88201 A	09-09-1994
			MX 9207152 A	01-07-1993
			NO 302099 B	26-01-1998
			NZ 245421 A	27-11-1995
			NZ 270729 A	27-11-1995
			PT 547000 T	30-06-2000
			RO 111542 B	29-11-1996
			RU 2121835 C	20-11-1998
			SK 363392 A	09-11-1994
			US 5356896 A	18-10-1994
			ZA 9209642 A	13-06-1994
WO 0021525	A	20-04-2000	AU 6090999 A	01-05-2000
US 5225202	A	06-07-1993	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**